RxDoctor Payments Data

Michael Mayes, MD

Internal Medicine · Hilton Head, SCNPI 1275627077

Payments from drug & device makers

$446in general payments, 2019–2025

Across 30 payments — averaging $14.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$106
  • Amgen$79
  • Pfizer$44
  • Amarin Pharma, Inc.$39
  • AbbVie$37
  • AstraZeneca$27
  • plus $115 from 8 others

What the payments were for

  • Food & beverage$43297%
  • Education$153%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$446 in reported general payments places this provider in the 55th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$40,584
Medicare patients
197
Services billed
457

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban82$83,402
OzempicSemaglutide27$33,048
JanuviaSitagliptin Phosphate37$28,333
Repatha PushtronexEvolocumab34$23,159
XareltoRivaroxaban15$21,717
Repatha SureclickEvolocumab20$20,825
JardianceEmpagliflozin17$18,260
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$14,600
TradjentaLinagliptin23$13,137
MyrbetriqMirabegron14$11,645
Fenofibrate22$9,530
VascepaIcosapent Ethyl17$9,122
Rosuvastatin Calcium242$5,152
Ezetimibe123$4,401
Nebivolol Hcl63$3,791

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$44$83,40282 claims
Novo NordiskOzempic$13$33,04827 claims
GSKTrelegy Ellipta$106$14,60016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Hilton Head

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →